Literature DB >> 21279449

Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans' cell histiocytosis.

Athanasios D Anastasilakis1, Gregory A Kaltsas, Georgios Delimpasis, Ludwig Wilkens, George Kanakis, Polyzois Makras.   

Abstract

We present a 22-year old male patient previously treated with radiotherapy and surgery at the age of 7 for an undefined suprachiasmatic mass. Following treatment he gradually became morbidly obese and besides subsequent panhypopituitarism he achieved his target height probably due to obesity-induced severe hyperinsulinemia. At the age of 21 Langerhans' cell histiocytosis was diagnosed at the right mandible and was surgically treated. One year later he developed a further painful osteolytic hip lesion and a single zoledronate infusion eliminated all symptoms. We highlight the importance of obtaining a histological diagnosis before initiating treatment, and the distinctive course of the disease in a patient who continued to growth besides GH deficiency.

Entities:  

Mesh:

Year:  2012        PMID: 21279449     DOI: 10.1007/s11102-011-0291-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  14 in total

1.  Treatment of Langerhans cell histiocytosis with pamidronate.

Authors:  R P Farran; E Zaretski; R M Egeler
Journal:  J Pediatr Hematol Oncol       Date:  2001-01       Impact factor: 1.289

2.  More on pamidronate in Langerhans'-cell histiocytosis.

Authors:  R E Brown
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

3.  Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis.

Authors:  K Arzoo; S Sadeghi; V Pullarkat
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

4.  Bisphosphonates as antialveolar macrophage therapy in pulmonary langerhans cell histiocytosis?

Authors:  R E Brown
Journal:  Med Pediatr Oncol       Date:  2001-06

5.  Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment.

Authors:  Jean Donadieu; Maria-Alejandra Rolon; Isabelle Pion; Caroline Thomas; François Doz; Mohamed Barkaoui; Alain Robert; Anne Deville; Françoise Mazingue; Michel David; Raja Brauner; Sylvie Cabrol; Catherine Garel; Michel Polak
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

6.  Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH).

Authors:  P Makras; C Samara; M Antoniou; A Zetos; D Papadogias; Z Nikolakopoulou; E Andreakos; G Toloumis; G Kontogeorgos; G Piaditis; G A Kaltsas
Journal:  Neuroradiology       Date:  2005-11-15       Impact factor: 2.804

Review 7.  Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society.

Authors:  B E Favara; A C Feller; M Pauli; E S Jaffe; L M Weiss; M Arico; P Bucsky; R M Egeler; G Elinder; H Gadner; M Gresik; J I Henter; S Imashuku; G Janka-Schaub; R Jaffe; S Ladisch; C Nezelof; J Pritchard
Journal:  Med Pediatr Oncol       Date:  1997-09

8.  Growth without growth hormone (GH): a case report.

Authors:  Polyzois Makras; Dimitris Papadogias; Grigoris Kaltsas; Nikolaos Kaklas; Georgios Piaditis
Journal:  Hormones (Athens)       Date:  2004 Oct-Dec       Impact factor: 2.885

Review 9.  Endocrine manifestations in Langerhans cell histiocytosis.

Authors:  Polyzois Makras; Krystallenia I Alexandraki; George P Chrousos; Ashley B Grossman; Gregory A Kaltsas
Journal:  Trends Endocrinol Metab       Date:  2007-06-27       Impact factor: 12.015

10.  Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone.

Authors:  C L M H Gibbons; M Petra; R Smith; N A Athanasou
Journal:  Sarcoma       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.